

Corporate Presentation

April 2024

scPharmaceuticals

Innovative outpatient solutions that bring care closer to home

Disclaimer

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our launch and commercialization plans, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding business strategy, product approval, current and prospective collaborations, timing and likelihood of success, expectations regarding market acceptance and size, plans for launch and commercialization, plans and objectives of management for future operations, the Company's financial position and future results of anticipated product candidates, are forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forwardlooking statements. These risks and uncertainties include, but are not limited to, the risk of delays in our commercialization activities for FUROSCIX, the risk that FUROSCIX does not gain market acceptance, our ability to manufacture or obtain sufficient supply for commercialization of FUROSCIX, the risk that we do not generate substantial revenues, our limited operating history and lack of experience commercialization pharmaceutical products, our history of significant operating losses and the risk that we may never achieve profitability, our need for additional funding, which may not be available, the risk that we do not obtain regulatory approval for our product candidates or, if approved, the successful commercialization of such products, including market acceptance and expected payer cost savings, the risk of cessation or delay of any of our ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our product candidates, our ability to protect our intellectual property and proprietary technology, our ability to comply with our intellectual property licenses, our dependence on third parties, potential product liability lawsuits, failure to identify and develop additional product candidates, our dependence on our executive officers, directors and principal consultants, and the impact of the COVID-19 pandemic on our business, operations and projected financial guidance. For a discussion of these and other risks and uncertainties, and other important factors, see the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated in the Company's Quarterly Report on Form 10-Q for the guarter ended September 30, 2022, as well as other risks detailed in the Company's subsequent filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company is responsible for the accuracy of these statements and believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Optimizing Delivery to Advance Patient Care

FUROSCIX launched in February 2023 to treat congestion in heart failure, a \$9.4B market

Continued strong commercial and operational execution

\$13.6M net revenues in 2023 and auto-injector sNDA submission by YE:24

Several label expansion initiatives underway

A) Class IV heart failure, representing 10% of all HF patients B) fluid overload in CKD, a \$3B market



Robust intellectual property coverage through 2034

Strong financial position

Cash, cash equivalents and short-term investments of \$76 million as of December 31, 2023

scPharmaceuticals

Large Unmet Need in Heart Failure


Significant global market opportunity with a clear value proposition

- 6.7 and 15.8 million adults with HF in the US¹ and G7², respectively
- In the US, 4.0 million HF events occur annually^{1,2,3,4}, with congestion as the most common cause of hospitalization⁵
- In patients 65+ of age, congestion from worsening HF is also one of the most common causes of hospitalization
- HF represents 33% (\$123B) of annual Medicare Part A and B spend⁶
- Potential for significant cost savings for payers and hospitals by reducing patient hospital admission/readmission rates

\$9.4B Addressable US market opportunity

^{1.} Tsao, CW et al. Circulation, 25 Jan. 2023. 2. Decision Resource Group Report 2022 HF Disease Landscape & Forecast, note: G7=US, Germany, France, UK, Italy, Spain, Japan equals 15.8M cases 3. Virani, et. al. Circulation 2020;:e374 HF clinic visits. 4. Data on file. scPharmaceuticals, Burlington, MA. 5. Mullens W, et al. Eur J Heart Fail 2019; 21(2):137-155. 6. Fitch, et al. Cost Burden of Worsening Heart Failure in the Medicare fee for service population, Milliman, 2017. http://us.milliman.com/insight/2017/The-cost-burden-of-worsening-heart-failure-in-the-Medicare-fee-for-service-population-An-actuarial-analysis/

Heart Failure (HF): A Significant Financial Burden to Medicare




HF patients represent 33% (\$123B) of annual Medicare Part A and B spending¹

Average cost of a heart failure hospitalization is \$11,8401

80% of HF costs is attributed to the hospitalization cost¹

1. Fitch, et al. Cost Burden of Worsening Heart Failure in the Medicare fee for service population, Milliman, 2017 (White Paper). ScPharmaceuticals

Cycle of Decompensation & Hospitalization Is the Primary Burden for Patients Suffering from HF



1. Bennett S, et al. American Journal of Crit Care. 1998;7(3):168-174. 2. Collins et al. J Am Coll Cardiol. 2013 January 15; 61(2): 121–126. 3. Neuenschwander JF, et al. Crit Care Clin. 2007;23(4):737-58. 4. Costanzo MR, et al. Am Heart J. 2007;154(2):267-77. 5. Fonarow GC, et al. JAMA. 2005;293(5):572-80 6. Kilgore M et al. *Risk Manag Healthc Policy*. 2017;10:63..7. Fitch K, et al (2017) The cost burden of worsening heart failure in the Medicare fee for service population: an actuarial analysis [white paper]

New Model of Treatment

<u>sc</u>Pharmaceuticals

FUROSCIX Opportunity for Intervention

Pre-admission and post-discharge (readmission) are targeted opportunities for Worsening Heart Failure (WHF) intervention



A New Model for Treating Congestion in Heart Failure

- Furosemide pH neutral subcutaneous injection
- Indicated to treat congestion due to fluid overload in adult patients with NYHA1 Class II/III chronic heart failure
- On-Body Infusor delivers 80 mg/10 mL dose over 5-hours in biphasic delivery profile
 - 30 mg delivered in the first hour, 12.5 mg delivered per hour over the subsequent four hours
- Absolute bioavailability: 99.6% (90% CI for AUC: 94.8-104.8%)1
- Equivalent diuresis and natriuresis to IV furosemide
- FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema





5-hour Infusion of FUROSCIX Resulted in Nearly Complete Bioavailability vs. Two Bolus IV Injections of Furosemide

	FUROSCIX SC 5-hour, 80 mg infusion (n = 15) ^a	IV bolus furosemide 2-40 mg injection (n = 15) ^a
C _{max} , ng/mL Mean ± SD	2040 ± 449	8580 ± 2540
t _{max} , h Median (min–max)	4.00 (1.00–5.08)	2.08 (0.08–2.08)
AUC _{last} , h*ng/mL Mean (SD)	13000 ± 4000	13000 ± 4050
AUC∞, h*ng/mL Mean (SD)	13100 ± 4010	13200 ± 4170

Absolute bioavailability: 99.6% (90% CI for AUC: 94.8-104.8%)

FUROSCIX: Effective, Safe and Reduces HC System Costs

Outcomes of Phase II pilot and health economic studies provide clinical and economic validation for the use of FUROSCIX

Phase II AT HOME-HF Study FUROSCIX subjects demonstrate augmented decongestion vs. enhanced oral divretics

- Primary endpoint win-ratio for the hierarchal composite endpoint was 1.11
 - 37% relative risk reduction in heart failure hospitalizations
- Secondary endpoints highlight significant lifestyle improvements:
 - ~4 ½ pound greater weight loss at day 3 (p=0.035)
 - Improvement in 5-point and 7-point dyspnea score at day 3 (p=0.019 and p=0.006, respectively)
 - Clinically relevant increase in KCCQ scores of 8.9 points and 9.3 points at day 7 and day 30 from baseline, respectively
 - 55.8-meter improvement in 6-minute walk distance at day 30 (p=0.012)
- Acceptable tolerability profile and consistent with prior studies and reported AEs

FREEDOM-HF Study


FUROSCIX outside of the hospital setting shows potential to significantly reduce healthcare costs

Average 30-day HF-related and overall healthcare costs reduced by \$16,995 and \$27,840, respectively, vs. historically matched comparators (p < 0.0001)

Commercial Opportunity

Multi-Billion-Dollar Annual U.S. Market Opportunity

Potential paradigm shift in how heart failure is treated



*\$898 per dose; assumes average of 5 doses per HF episode

Targeted opportunities for HF intervention: Prevention of admissions and readmissions

scPharmaceuticals

1. Decision Resources Group Report 2023 diagnosed events of Acute HF in the US for 2022 and HF prevalence of 7.2M cases 3. Virani, et. al. Circulation 2020;:2.374 MHF clinic visits 3. H-CUP 2017 Inpatient Stays HF principal diagnosis 1M primary HF diagnosis 4. Market Research Data on file. scPharmaceuticals, Burlington, MA used in calculation of 4.1M HF episodes and 2.1M addressable episodes

Stakeholders are Aligned on the Need to Reduce Hospitalizations and Treatment Costs

+ ≣\$ Payer


- Average cost to Medicare for an HF admission is \$11,840¹
- HF is top condition targeted by CMS Hospital Readmission Reduction Program² (HRRP)
- Medicare Advantage plans bear both medical and pharmacy costs

Hospital and HCP

- Average length of stay is 5.24 days with DRG only reimbursing 3.9 days⁵
- Increased financial exposure for hospitals and providers based on readmission penalty risk
- HF in-patient care represents multi-milliondollar loss for targeted hospitals
- HRRP² introduces potential for substantial financial penalties

^{1.} Fitch, et al. Cost Burden of Worsening Heart Failure in the Medicare fee for service population, Milliman, 2017. http://us.milliman.com/insight/2017/The-cost-burden-of-worsening-heart-failure-in-the-Medicare-fee-for-service-population-An-actuarialanalysis/ 2. Readmission Reduction Program (HRRP) (updated 2018, April 27) Retrieved from https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html 3. Quality Payment Program from CMS https://qpp.cms.gov/ 4. Agency for Healthcare Research and Quality (AHRQ). HCUP National Inpatient Sample (NIS), 2014 5. Data on file.scPharmaceuticals, Burlington, MA.


Doses Written by Quarter Since Launch



scPharmaceuticals

Doses Filled by Quarter Since Launch

Doses Filled





Net Revenue

GTN Discount

\$6.1M in Q4:23

18% from launch through Q4:23

VS.

~60% QoQ Growth vs. Q3:23

21% from launch through Q3:23

scPharmaceuticals

Driving Commercial Success in Heart Failure in 2024

Label Expansion into Class IV HF

Class IV represents 10% of all HF patients Extend Commercial Reach Through Sales Force Expansion

Potential to expand from 68 current territories Drive New Writers & Accounts Across HF Clinics and Cardiologists

> 77% new prescriber

growth in Q3:2023

Increase Formulary Status with Major PBMs to >75%

Goal of lowering patient co-pay to \$100 or less Continue Signing Up New Integrated Delivery Networks

Pull through existing contracts with VA & Kaiser

Long Term Growth Initiatives

Long-Term Growth Initiatives

80 mg / 1 mL	FUROSCIX Label Expansions				
Auto Injector	NYHA Class IV Heart Failure	Chronic Kidney Disease (CKD)			
Pivotal pharmacokinetic (PK) data expected in 2024	Submitted sNDA to FDA in October 2023	FDA has confirmed no additional clinical studies required			
Expected sNDA submission to FDA by end of 2024	Expected FDA approval by August 2024 (at the latest)	Only need to demonstrate adequate PK and PD bridge to furosemide injection (listed drug)			
Potential to significantly reduce manufacturing costs		Expected sNDA submission to FDA by March/April 2024			
		Expected commercial launch in Q4:24 / Q1:25			


80mg/1mL Auto Injector

- Pivotal pharmacokinetic (PK) data expected in 2024
- sNDA submission anticipated 2nd half of 2024
- Formulation patent 2040
- Reduces COGs by ~70%
- Enhances patient and health care providers options



FUROSCIX Multi-Billion-Dollar Annual Market Opportunity in Chronic Kidney Disease Patients Without Heart Failure

Potential paradigm shift in how CKD edema is treated



*\$898 per dose; assumes average of 5 doses per CKD episode

2023 CKD Market and Landscape Forecast – Clarivate/DRG

SC Pharmaceuticals 2015–2018 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation

Thanakitcharu (2014) Early Detection of Subclinical Edema in Chronic Kidney Disease Patients by Bioelectrical Impedance Analysis - J Med Assoc Thai 2014; 97 (Suppl. 11): S1-S10

Multiple Upcoming Milestones in CKD





12-Month Catalysts

Chronic Kidney Disease (CKD) NDA Filing Submitted			Pivotal PK Study Results Due		Auto Injector NDA Submission		
April 2024	May 2024	July 2024	August 2024	De	ecember 2024	February 2025	
Anticipated CKD NDA Submission Accepted		Anticipated NYHA Class IV Approval			Anticipated CKD PDUFA		

Summary

- Net revenue of \$13.6M from launch through Q4
 - 60% sequential growth from Q₃ to Q₄
- Gross-to-net discount of 18% from launch through Q4
- Filed sNDA for expansion into Class IV heart failure in October 2023
 - Approval expected mid-year 2024
- On track to file label expansion in CKD in first half of 2024
- PK study results of Auto Injector program in Q3 2024
- NDA anticipated for Auto Injector in Q4 2024